Tag: xifin inc.

Test price data shows major difference between Medicare lab fee schedule and private payers

This is an excerpt from a 1,500-word article in the November 7 issue of THE DARK REPORT. The complete article is available for a limited time to all readers, and available at all times to paid members of the Dark Intelligence Group.
CEO SUMMARY: THE DARK REPORT presents the lab industry’s first look at actual price data

View Article

Market Price Data Sample from: Pain Management/Toxicology Labs

Here is the market price data for paint management and toxicology labs from XIFIN Inc. Lâle White, Founder and CEO of XIFIN, discusses the data with THE DARK REPORT.

EDITOR: Before we discuss XIFIN’s analysis of what PAMA market price reporting will look like for labs involved in pain management testing and toxicology, I think it is appropriate to recognize that

View Article

Market Price Data Sample from: Molecular/Genetic Labs

Here is the market price data for molecular and genetic labs from XIFIN Inc. Lâle White, Founder and CEO of XIFIN, discusses the data with THE DARK REPORT.

EDITOR: When you did this analysis of molecular and genetic testing labs, what caught your attention

WHITE: The issue for us is that Medicare made significant cuts in molecular and genetic test prices, but

View Article

Form 5010 Update: Medicare Extends 5010 Implementation For a Second Time, Effective July 1, 2012 – The Dark Report April 21, 2012

CEO SUMMARY: FACED WITH THE FACT that many payers were not ready to implement the 5010 standard under the Health Insurance Portability and Affordability Act (HIPAA), on March 15, the federal Centers for Medicare & Medicaid Services (CMS) announced a second delay in enforcement of the standard. The extension is until June 30. (TDR interviews Matt Warner,

View Article

Price Cuts, Long Delays in Payment Are Expected – December 31, 2012

CEO SUMMARY:  In addition to a steep cut in the 88305 CPT code, anatomic pathology laboratories can expect cuts in the payment from Medicare for molecular and prostate biopsy testing. Two national experts in lab billing and reimbursement warn labs to expect confusion in how both public and private payers implement these new policies. Overall,

View Article